Alcon Inc. (ALC)
NYSE · Healthcare · Medical - Specialties
Profile
Alcon Inc.
- Exchange
- NYSE
- Ticker
- ALC
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Country
- CH
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Key facts
Alcon Inc.: key facts
- Alcon Inc. (NYSE: ALC) is a Medical - Specialties company in the Healthcare sector.
- In fiscal 2025, Alcon Inc. reported revenue of $10.4B and net income of $980.0M.
- Revenue grew 5.8% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $10.8B and net income was $639.3M.
MonkScore
Alcon Inc.'s MonkScore
MonkScore
MonkScore range: 30–40
as of October 2026
Sector rank: 423 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth30–40
- Profitability30–40
- Quality70–80
- Market Conviction40–50
- Safety10–20
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Alcon Inc.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $10.8B | $10.4B | $9.9B | $9.5B | $8.7B | $8.3B |
| Gross profit | $6.1B | $5.7B | $5.5B | $5.2B | $4.7B | $4.7B |
| Operating income | $1.1B | $1.4B | $1.4B | $1.0B | $672.0M | $580.0M |
| Net income | $639.3M | $980.0M | $1.0B | $974.0M | $335.0M | $376.0M |
| Operating cash flow | $2.3B | $2.3B | $2.1B | $1.4B | $1.2B | $1.3B |
| Capital expenditure | -$593.4M | -$663.0M | -$670.0M | -$851.0M | -$745.0M | -$1.2B |
| Free cash flow | $1.7B | $1.6B | $1.4B | $537.0M | $472.0M | $165.0M |
| Total debt | $5.3B | $5.2B | $5.1B | $5.1B | $5.1B | $4.5B |
| Cash | $1.4B | $1.5B | $1.7B | $1.1B | $980.0M | $1.6B |
Revenue growth a year
- 1-year
- 4.9%
- 3-year
- 6.1%
- 4-year
- 5.8%
Compound growth between fiscal years.
Peers
Similar companies
- STERIS plcNYSE:STEMonkScore range: 40–50
- 908 Devices Inc.NASDAQ:MASSMonkScore range: 40–50
- Mesa Laboratories, Inc.NASDAQ:MLABMonkScore range: 60–70
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.